{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T10:19:28Z","timestamp":1791368368073,"version":"4.3.1"},"reference-count":213,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T00:00:00Z","timestamp":1470873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T00:00:00Z","timestamp":1470873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Ricerca Corrente IRCCS Istituto Auxologico Italiano"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s12016-016-8582-3","type":"journal-article","created":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T03:09:17Z","timestamp":1470884957000},"page":"401-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review"],"prefix":"10.1007","volume":"52","author":[{"given":"Cecilia Beatrice","family":"Chighizola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voon H.","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Meroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,11]]},"reference":[{"key":"8582_CR1","first-page":"S83","volume":"15","author":"GF Ferraccioli","year":"1997","unstructured":"Ferraccioli GF, Bambara LM, Ferraris M, Perpignano G, Cattaneo R, Porzio F, Accardo S, Mattara L, Zoppini A, Benucci M, Ostuni PA, Pasero G (1997) Effects of cyclosporin on joint damage in rheumatoid arthritis. The Italian Rheumatologists Study Group on Rheumatoid Arthritis. Clin Exp Rheumatol 15:S83\u2013S89","journal-title":"Clin Exp Rheumatol"},{"key":"8582_CR2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jaad.2010.02.063","volume":"63","author":"KT Amor","year":"2010","unstructured":"Amor KT, Ryan C, Menter A (2010) The use of cyclosporine in dermatology: part I. J Am Acad Dermatol 63:925\u2013946","journal-title":"J Am Acad Dermatol"},{"key":"8582_CR3","first-page":"125","volume":"47","author":"X Zhang","year":"2008","unstructured":"Zhang X, Cui J, Qiu M-C, Li D-Q, Zhang P, Zhang J-S (2008) The effects of cyclosporine A on immunoglobulins deposition in retina of streptozotocin-induced diabetic rats. Zhonghua Nei Ke Za Zhi 47:125\u2013128","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"8582_CR4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O\u2019Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG (2012) 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64:625\u2013639","journal-title":"Arthritis Care Res"},{"key":"8582_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/art.1780300111","volume":"30","author":"M Dougados","year":"1987","unstructured":"Dougados M, Amor B (1987) Cyclosporin A in rheumatoid arthritis: preliminary clinical results of an open trial. Arthritis Rheum 30:83\u201387","journal-title":"Arthritis Rheum"},{"key":"8582_CR6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/ard.48.7.550","volume":"48","author":"M Dougados","year":"1989","unstructured":"Dougados M, Duchesne L, Awada H, Amor B (1989) Assessment of efficacy and acceptability of low dose cyclosporin in patients with rheumatoid arthritis. Ann Rheum Dis 48:550\u2013556","journal-title":"Ann Rheum Dis"},{"key":"8582_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/art.1780300102","volume":"30","author":"ME Weinblatt","year":"1987","unstructured":"Weinblatt ME, Coblyn JS, Fraser PA, Anderson RJ, Spragg J, Trentham DE, Austen KF (1987) Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum 30:11\u201317","journal-title":"Arthritis Rheum"},{"key":"8582_CR8","first-page":"1485","volume":"18","author":"R Madhok","year":"1991","unstructured":"Madhok R, Torley HI, Capell HA (1991) A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis. J Rheumatol 18:1485\u20131489","journal-title":"J Rheumatol"},{"key":"8582_CR9","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0140-6736(90)92630-Z","volume":"335","author":"P Tugwell","year":"1990","unstructured":"Tugwell P, Bombardier C, Gent M, Bennett KJ, Bensen WG, Carette S, Chalmers A, Esdaile JM, Klinkhoff AV, Kraag GR et al (1990) Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 335:1051\u20131055","journal-title":"Lancet"},{"key":"8582_CR10","first-page":"815","volume":"18","author":"AW van Rijthoven","year":"1991","unstructured":"van Rijthoven AW, Dijkmans BA, Th\u00e8 HS, Meijers KA, Montnor-Beckers ZL, Moolenburgh JD, Boers M, Cats A (1991) Comparison of cyclosporine and D-penicillamine for rheumatoid arthritis: a randomized, double blind, multicenter study. J Rheumatol 18:815\u2013820","journal-title":"J Rheumatol"},{"key":"8582_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s002960050113","volume":"19","author":"AA Drosos","year":"2000","unstructured":"Drosos AA, Voulgari PV, Katsaraki A, Zikou AK (2000) Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study. Rheumatol Int 19:113\u2013118","journal-title":"Rheumatol Int"},{"key":"8582_CR12","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/art.1780390618","volume":"39","author":"G Pasero","year":"1996","unstructured":"Pasero G, Priolo F, Marubini E, Fantini F, Ferraccioli G, Magaro M, Marcolongo R, Oriente P, Pipitone V, Portioli I, Tirri G, Trotta F, Della Casa-Alberighi O (1996) Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 39:1006\u20131015","journal-title":"Arthritis Rheum"},{"key":"8582_CR13","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/art.1780371015","volume":"37","author":"O F\u00f8rre","year":"1994","unstructured":"F\u00f8rre O (1994) Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group. Arthritis Rheum 37:1506\u20131512","journal-title":"Arthritis Rheum"},{"key":"8582_CR14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/rheumatology\/37.8.874","volume":"37","author":"HK Zeidler","year":"1998","unstructured":"Zeidler HK, Kvien TK, Hannonen P, Wollheim FA, F\u00f8rre O, Geidel H, Hafstr\u00f6m I, Kaltwasser JP, Leirisalo-Repo M, Manger B, Laasonen L, Markert ER, Prestele H, Kurki P (1998) Progression of joint damage in early active severe rheumatoid arthritis during 18\u00a0months of treatment: comparison of low-dose cyclosporin and parenteral gold. Br J Rheumatol 37:874\u2013882","journal-title":"Br J Rheumatol"},{"key":"8582_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/ard.61.6.511","volume":"61","author":"TK Kvien","year":"2002","unstructured":"Kvien TK, Zeidler HK, Hannonen P, Wollheim FA, F\u00f8rre O, Hafstr\u00f6m I, Kaltwasser JP, Leirisalo-Repo M, Manger B, Laasonen L, Prestele H, Kurki P (2002) Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension. Ann Rheum Dis 61:511\u2013516","journal-title":"Ann Rheum Dis"},{"key":"8582_CR16","first-page":"19","volume":"18","author":"AW van Rijthoven","year":"1991","unstructured":"van Rijthoven AW, Dijkmans BA, Goei Th\u00e9 HS, Boers M, Cats A (1991) Longterm cyclosporine therapy in rheumatoid arthritis. J Rheumatol 18:19\u201323","journal-title":"J Rheumatol"},{"key":"8582_CR17","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/BF02249021","volume":"13","author":"K Kr\u00fcger","year":"1994","unstructured":"Kr\u00fcger K, Schattenkirchner M (1994) Comparison of cyclosporin A and azathioprine in the treatment of rheumatoid arthritis\u2014results of a double-blind multicentre study. Clin Rheumatol 13:248\u2013255","journal-title":"Clin Rheumatol"},{"key":"8582_CR18","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1445-5994.1991.tb01405.x","volume":"21","author":"MJ Ahern","year":"1991","unstructured":"Ahern MJ, Harrison W, Hollingsworth P, Bradley J, Laing B, Bayliss C (1991) A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis. Aust N Z J Med 21:844\u2013849","journal-title":"Aust N Z J Med"},{"key":"8582_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/art.1780300112","volume":"30","author":"O F\u00f8rre","year":"1987","unstructured":"F\u00f8rre O, Bjerkhoel F, Salvesen CF, Berg KJ, Rugstad HE, Saelid G, Mellbye OJ, K\u00e5ss E (1987) An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: a preliminary report. Arthritis Rheum 30:88\u201392","journal-title":"Arthritis Rheum"},{"key":"8582_CR20","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1136\/ard.2009.124065","volume":"69","author":"MF Bakker","year":"2010","unstructured":"Bakker MF, Jacobs JWG, Welsing PMJ, van der Werf JH, Linn-Rasker SP, van der Veen MJ, Lafeber FP, Bijlsma JW, Utrecht Arthritis Cohort Study Group (2010) Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis 69:1849\u20131852","journal-title":"Ann Rheum Dis"},{"key":"8582_CR21","first-page":"695","volume":"16","author":"AA Drosos","year":"1998","unstructured":"Drosos AA, Voulgari PV, Papadopoulos IA, Politi EN, Georgiou PE, Zikou AK (1998) Cyclosporine A in the treatment of early rheumatoid arthritis. A prospective, randomized 24-month study. Clin Exp Rheumatol 16:695\u2013701","journal-title":"Clin Exp Rheumatol"},{"key":"8582_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/art1.10245","volume":"47","author":"A Marchesoni","year":"2002","unstructured":"Marchesoni A, Battafarano N, Arreghini M, Pellerito R, Cagnoli M, Prudente P, Cerase A, Priolo F, Tosi S (2002) Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis. Arthritis Rheum 47:59\u201366","journal-title":"Arthritis Rheum"},{"key":"8582_CR23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00296-003-0384-2","volume":"25","author":"P Sarzi-Puttini","year":"2005","unstructured":"Sarzi-Puttini P, D\u2019Ingianna E, Fumagalli M, Scarpellini M, Fiorini T, Ch\u00e9ri\u00e9-Ligni\u00e8re EL, Panni B, Fiorentini F, Corbelli V, Beyene NB, Mastaglio C, Severi C, Locati M, Cazzola M, Menozzi G, Monti G, Saccardo F, Alfieri G, Atzeni F (2005) An open, randomized comparison study of cyclosporine A, cyclosporine A\u2009+\u2009methotrexate and cyclosporine A\u2009+\u2009hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int 25:15\u201322","journal-title":"Rheumatol Int"},{"key":"8582_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.arcmed.2003.07.008","volume":"35","author":"JM Miranda","year":"2004","unstructured":"Miranda JM, Alvarez-Nemegyei J, Saavedra MA, Ter\u00e1n L, Galv\u00e1n-Villegas F, Garc\u00eda-Figueroa J, Jara LJ, Barile L, GRECIA Group (2004) A randomized, double-blind, multicenter, controlled clinical trial of cyclosporine plus chloroquine vs. cyclosporine plus placebo in early-onset rheumatoid arthritis. Arch Med Res 35:36\u201342","journal-title":"Arch Med Res"},{"key":"8582_CR25","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/rheumatology\/35.11.1142","volume":"35","author":"G Bendix","year":"1996","unstructured":"Bendix G, Bjelle A (1996) Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: a double-blind placebo-controlled study. Br J Rheumatol 35:1142\u20131149","journal-title":"Br J Rheumatol"},{"key":"8582_CR26","first-page":"1493","volume":"25","author":"BE van den Borne","year":"1998","unstructured":"van den Borne BE, Landew\u00e9 RB, Goei Th\u00e9 HS, ietveld JH, Zwinderman AH, Bruyn GA, Breedveld FC, Dijkmans BA (1998) Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol 25:1493\u20131498","journal-title":"J Rheumatol"},{"key":"8582_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1136\/ard.62.4.291","volume":"62","author":"AH Gerards","year":"2003","unstructured":"Gerards AH, Landew\u00e9 RBM, Prins APA, Bruyn GA, Goei Th\u00e9 HS, Laan RF, Dijkmans BA (2003) Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 62:291\u2013296","journal-title":"Ann Rheum Dis"},{"key":"8582_CR28","first-page":"2034","volume":"21","author":"W Bensen","year":"1994","unstructured":"Bensen W, Tugwell P, Roberts RM, Ludwin D, Ross H, Grace E, Gent M (1994) Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies). J Rheumatol 21:2034\u20132038","journal-title":"J Rheumatol"},{"key":"8582_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/03009749609082662","volume":"25","author":"F Salaffi","year":"1996","unstructured":"Salaffi F, Carotti M, Cervini C (1996) Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis. Scand J Rheumatol 25:16\u201323","journal-title":"Scand J Rheumatol"},{"key":"8582_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJM199507203330301","volume":"333","author":"P Tugwell","year":"1996","unstructured":"Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, McKendry R, Tesser J, Baker P, Wells G (1996) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 333:137\u2013141","journal-title":"N Engl J Med"},{"key":"8582_CR31","first-page":"486","volume":"33","author":"G Karanikolas","year":"2006","unstructured":"Karanikolas G, Charalambopoulos D, Andrianakos A, Antoniades C, Katsilambros N (2006) Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. J Rheumatol 33:486\u2013489","journal-title":"J Rheumatol"},{"key":"8582_CR32","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/art.21796","volume":"54","author":"ML Hetland","year":"2006","unstructured":"Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Skj\u00f8dt H, Pedersen JK, Lauridsen UB, Svendsen A, Tarp U, P\u00f8denphant J, Hansen G, Lindegaard H, de Carvalho A, \u00d8stergaard M, H\u00f8rslev-Petersen K, CIMESTRA Study Group (2006) Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 54:1401\u20131409","journal-title":"Arthritis Rheum"},{"key":"8582_CR33","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1093\/rheumatology\/keg394","volume":"42","author":"A Marchesoni","year":"2003","unstructured":"Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S (2003) Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology (Oxford) 42:1545\u20131549","journal-title":"Rheumatology (Oxford)"},{"key":"8582_CR34","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1136\/ard.2007.076299","volume":"67","author":"EHS Choy","year":"2007","unstructured":"Choy EHS, Smith CM, Farewell V, Walker D, Hassell A, Chau L, Scott DL, CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group, CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arhritis) Trial Group (2007) Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Ann Rheum Dis 67:656\u2013663","journal-title":"Ann Rheum Dis"},{"key":"8582_CR35","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/ard.2009.125534","volume":"69","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, Hansen I, Skj\u00f8dt H, Pedersen JK, Lauridsen UB, Svendsen A, Tarp U, P\u00f8denphant J, Hansen G, Lindegaard H, de Carvalho A, \u00d8stergaard M, H\u00f8rslev-Petersen K, CIMESTRA Study Group (2010) Radiographic progression and remission rates in early rheumatoid arthritis\u2014MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial. Ann Rheum Dis 69:1789\u20131795","journal-title":"Ann Rheum Dis"},{"key":"8582_CR36","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1002\/art.1780401018","volume":"40","author":"CM Stein","year":"1997","unstructured":"Stein CM, Pincus T, Yocum D, Tugwell P, Wells G, Gluck O, Kraag G, Torley H, Tesser J, McKendry R, Brooks RH (1997) Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum 40:1843\u20131851","journal-title":"Arthritis Rheum"},{"key":"8582_CR37","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1093\/rheumatology\/41.8.892","volume":"41","author":"GF Ferraccioli","year":"2002","unstructured":"Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E (2002) Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 41:892\u2013898","journal-title":"Rheumatology (Oxford)"},{"key":"8582_CR38","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1136\/ard.2005.036152","volume":"65","author":"PI Sidiropoulos","year":"2006","unstructured":"Sidiropoulos PI, Siakka P, Raptopoulou A, Mamoulaki M, Choulaki C, Koutala H, Kouroumali H, Kritikos H, Boumpas DT (2006) An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab. Ann Rheum Dis 65:538\u2013541","journal-title":"Ann Rheum Dis"},{"key":"8582_CR39","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1136\/ard.61.9.822","volume":"61","author":"TI Temekonidis","year":"2002","unstructured":"Temekonidis TI, Georgiadis AN, Alamanos Y, Bougias DV, Voulgari PV, Drosos AA (2002) Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis 61:822\u2013825","journal-title":"Ann Rheum Dis"},{"key":"8582_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/039463201102400119","volume":"24","author":"A Migliore","year":"2011","unstructured":"Migliore A, Bizzi E, Massafra U, Vacca F, Martin Martin LS, Ferlito C, Podesta E, Granata M, Lagana B (2011) A new chance to maintain remission induced by anti-TNF agents in rheumatoid arthritis patients: CYnAR study II of a 12-month follow-up. Int J Immunopathol Pharmacol 24:167\u201374","journal-title":"Int J Immunopathol Pharmacol"},{"key":"8582_CR41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/039463201202500136","volume":"25","author":"A Picchianti Diamanti","year":"2012","unstructured":"Picchianti Diamanti A, Argento G, Podest\u00e0 E, Germano V, Fazi S, Migliore A, David V, D\u2019Amelio R, Lagan\u00e0 B (2012) Can the association of ciclosporine a and methotrexate maintain remission\/low disease activity induced by etanercept in early rheumatoid arthritis patients? Evaluation by magnetic resonance imaging. Int J Immunopathol Pharmacol 25:301\u2013305","journal-title":"Int J Immunopathol Pharmacol"},{"key":"8582_CR42","doi-asserted-by":"crossref","first-page":"iii51","DOI":"10.1136\/ard.60.90003.iii51","volume":"60","author":"MC Hochberg","year":"2001","unstructured":"Hochberg MC, Tracy JK, Flores RH (2001) \u201cStepping-up\u201d from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate. Ann Rheum Dis 60:iii51\u2013iii54","journal-title":"Ann Rheum Dis"},{"key":"8582_CR43","first-page":"472","volume":"35","author":"PS Helliwell","year":"2008","unstructured":"Helliwell PS, Taylor WJ, CASPAR Study Group (2008) Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs\u2014comparison of drugs and adverse reactions. J Rheumatol 35:472\u2013476","journal-title":"J Rheumatol"},{"key":"8582_CR44","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1084\/jem.193.5.607","volume":"193","author":"GL Hern\u00e1ndez","year":"2001","unstructured":"Hern\u00e1ndez GL, Volpert OV, I\u00f1iguez MA, Lorenzo E, Mart\u00ednez-Mart\u00ednez S, Grau R, Fresno M, Redondo JM (2001) Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 193:607\u2013620","journal-title":"J Exp Med"},{"key":"8582_CR45","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/art.10215","volume":"46","author":"M-L Cho","year":"2002","unstructured":"Cho M-L, Cho C-S, Min S-Y, Kim SH, Lee SS, Kim WU, Min DJ, Min JK, Youn J, Hwang SY, Park SH, Kim HY (2002) Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Arthritis Rheum 46:1202\u20131209","journal-title":"Arthritis Rheum"},{"key":"8582_CR46","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1136\/ard.2008.094946","volume":"68","author":"CT Ritchlin","year":"2009","unstructured":"Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, de Vlam K, Fiorentino D, Fitzgerald O, Gottlieb AB, McHugh NJ, Nash P, Qureshi AA, Soriano ER, Taylor WJ, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68:1387\u20131394","journal-title":"Ann Rheum Dis"},{"key":"8582_CR47","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/archderm.1989.01670160055007","volume":"125","author":"AK Gupta","year":"1989","unstructured":"Gupta AK, Matteson EL, Ellis CN, Ho VC, Tellner DC, Voorhees JJ, McCune WJ (1989) Cyclosporine in the treatment of psoriatic arthritis. Arch Dermatol 125:507\u2013510","journal-title":"Arch Dermatol"},{"key":"8582_CR48","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1136\/ard.49.8.603","volume":"49","author":"K Steinsson","year":"1990","unstructured":"Steinsson K, J\u00f3nsd\u00f3ttir I, Valdimarsson H (1990) Cyclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis 49:603\u2013606","journal-title":"Ann Rheum Dis"},{"key":"8582_CR49","first-page":"74","volume":"19","author":"C Salvarani","year":"1992","unstructured":"Salvarani C, Macchioni P, Boiardi L, Rossi F, Casadei Maldini M, Mancini R, Beltrandi E, Lodi L, Bisighini G, Portioli I (1992) Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy. J Rheumatol 19:74\u201379","journal-title":"J Rheumatol"},{"key":"8582_CR50","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.1365-2133.1996.tb03885.x","volume":"135","author":"G Mahrle","year":"1996","unstructured":"Mahrle G, Schulze HJ, Br\u00e4utigam M, Mischer P, Schopf R, Jung EG, Weidinger G, F\u00e4rber L (1996) Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre study. Br J Dermatol 135:752\u2013757","journal-title":"Br J Dermatol"},{"key":"8582_CR51","first-page":"589","volume":"13","author":"A Spadaro","year":"1995","unstructured":"Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A (1995) Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 13:589\u2013593","journal-title":"Clin Exp Rheumatol"},{"key":"8582_CR52","first-page":"2274","volume":"28","author":"C Salvarani","year":"2001","unstructured":"Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G, Cantini F, Salaffi F, Padula A, Lovino C, Dovigo L, Bordin G, Davoli C, Pasero G, Alberighi OD (2001) A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 28:2274\u20132282","journal-title":"J Rheumatol"},{"key":"8582_CR53","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/ard.2004.024463","volume":"64","author":"AD Fraser","year":"2005","unstructured":"Fraser AD, van Kuijk AWR, Westhovens R, Karim Z, Wakefield R, Gerards AH, Landew\u00e9 R, Steinfeld SD, Emery P, Dijkmans BA, Veale DJ (2005) A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 64:859\u2013864","journal-title":"Ann Rheum Dis"},{"key":"8582_CR54","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1136\/ard.2009.119446","volume":"69","author":"S D\u2019Angelo","year":"2010","unstructured":"D\u2019Angelo S, Cutro MS, Lubrano E, Leccese P, Mennillo GA, Ferrara N, Olivieri I (2010) Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis. Ann Rheum Dis 69:934\u2013935","journal-title":"Ann Rheum Dis"},{"key":"8582_CR55","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1136\/ard.2010.130864","volume":"70","author":"F Atzeni","year":"2011","unstructured":"Atzeni F, Boccassini L, Antivalle M, Salaffi F, Sarzi-Puttini P (2011) Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. Ann Rheum Dis 70:712\u2013714","journal-title":"Ann Rheum Dis"},{"key":"8582_CR56","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s00296-001-0166-7","volume":"21","author":"P Sarzi-Puttini","year":"2002","unstructured":"Sarzi-Puttini P, Cazzola M, Panni B, Turiel M, Fiorini T, Belai-Beyene N, Ch\u00e8ri\u00e9-Ligni\u00e8r\u00e9 EL (2002) Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. Rheumatol Int 21:234\u2013238","journal-title":"Rheumatol Int"},{"key":"8582_CR57","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s002960050050","volume":"18","author":"P Macchioni","year":"1998","unstructured":"Macchioni P, Boiardi L, Cremonesi T, Battistel B, Casadei-Maldini M, Beltrandi E, Mancini R, Salvarani C (1998) The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A. Rheumatol Int 18:27\u201333","journal-title":"Rheumatol Int"},{"key":"8582_CR58","first-page":"359","volume":"54","author":"D Israel-Biet","year":"1983","unstructured":"Israel-Biet D, No\u00ebl L-H, Bach MA, Dardenne M, Bach JF (1983) Marked reduction of DNA antibody production and glomerulopathy in thymulin (FTS-Zn) or cyclosporin A treated (NZB X NZW) F1 mice. Clin Exp Immunol 54:359\u2013365","journal-title":"Clin Exp Immunol"},{"key":"8582_CR59","first-page":"1","volume":"59","author":"MG Jones","year":"1985","unstructured":"Jones MG, Harris G (1985) Prolongation of life in female NZB\/NZW (F1) hybrid mice by cyclosporin A. Clin Exp Immunol 59:1\u20139","journal-title":"Clin Exp Immunol"},{"key":"8582_CR60","first-page":"225","volume":"64","author":"HC Gunn","year":"1986","unstructured":"Gunn HC (1986) Successful treatment of autoimmunity in (NZB X NZW) F1 mice with cyclosporin and (Nva2)-cyclosporin: I. Reduction of autoantibodies. Clin Exp Immunol 64:225\u2013233","journal-title":"Clin Exp Immunol"},{"key":"8582_CR61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0192-0561(81)90007-2","volume":"3","author":"DA Isenberg","year":"1981","unstructured":"Isenberg DA, Snaith ML, Morrow WJ, Al-Khader AA, Cohen SL, Fisher C, Mowbray J (1981) Cyclosporin A for the treatment of systemic lupus erythematosus. Int J Immunopharmacol 3:163\u2013169","journal-title":"Int J Immunopharmacol"},{"key":"8582_CR62","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S0022-3476(87)80057-4","volume":"111","author":"G Feutren","year":"1987","unstructured":"Feutren G, Querin S, No\u00ebl LH, Chatenoud L, Beaurain G, Tron F, Lesavre P, Bach JF (1987) Effects of cyclosporine in severe systemic lupus erythematosus. J Pediatr 111:1063\u20131068","journal-title":"J Pediatr"},{"key":"8582_CR63","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/BF01736809","volume":"65","author":"PA Miescher","year":"1987","unstructured":"Miescher PA, Favre H, Chatelanat F, Mihatsch MJ (1987) Combined steroid-cyclosporin treatment of chronic autoimmune diseases. Clinical results and assessment of nephrotoxicity by renal biopsy. Klin Wochenschr 65:727\u2013736","journal-title":"Klin Wochenschr"},{"key":"8582_CR64","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/art.1780370416","volume":"37","author":"M Tokuda","year":"1994","unstructured":"Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, Takahara J (1994) Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 37:551\u2013558","journal-title":"Arthritis Rheum"},{"key":"8582_CR65","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/art.1780400106","volume":"40","author":"D Caccavo","year":"1997","unstructured":"Caccavo D, Lagan\u00e0 B, Mitterhofer AP, Ferri GM, Afeltra A, Amoroso A, Bonomo L (1997) Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 40:27\u201335","journal-title":"Arthritis Rheum"},{"key":"8582_CR66","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1191\/096120398678919714","volume":"7","author":"C Dost\u00e1l","year":"1998","unstructured":"Dost\u00e1l C, Tesar V, Rychlik I, Zabka J, Vencovsk\u00fd J, Bart\u00fbnkov\u00e1 J, Stejskalov\u00e1 A, Tegzova D (1998) Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 7:29\u201336","journal-title":"Lupus"},{"key":"8582_CR67","first-page":"295","volume":"16","author":"PA Miescher","year":"1994","unstructured":"Miescher PA, Favre H, Lemoine R, Huang YP (1994) Drug combination therapy of systemic lupus erythematosus. Springer Semin Immunopathol 16:295\u2013311","journal-title":"Springer Semin Immunopathol"},{"key":"8582_CR68","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s005990070017","volume":"30","author":"F Dammacco","year":"2000","unstructured":"Dammacco F, Casa Alberighi Della O, Ferraccioli G, Racanelli V, Casatta L, Bartoli E (2000) Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. Int J Clin Lab Res 30:67\u201373","journal-title":"Int J Clin Lab Res"},{"key":"8582_CR69","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1136\/ard.59.6.487","volume":"59","author":"SJ Morton","year":"2000","unstructured":"Morton SJ, Powell RJ (2000) An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use. Ann Rheum Dis 59:487\u2013489","journal-title":"Ann Rheum Dis"},{"key":"8582_CR70","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrrheum.2013.157","volume":"10","author":"W Xiong","year":"2013","unstructured":"Xiong W, Lahita RG (2013) Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol 10:97\u2013107","journal-title":"Nat Rev Rheumatol"},{"key":"8582_CR71","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00467-010-1469-2","volume":"25","author":"A Bensman","year":"2010","unstructured":"Bensman A, Niaudet P (2010) Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies. Pediatr Nephrol 25:1197\u20131199","journal-title":"Pediatr Nephrol"},{"key":"8582_CR72","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nm.1857","volume":"14","author":"C Faul","year":"2008","unstructured":"Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14:931\u2013938","journal-title":"Nat Med"},{"key":"8582_CR73","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000168040","volume":"9","author":"H Favre","year":"1989","unstructured":"Favre H, Miescher PA, Huang YP, Chatelanat F, Mihatsch MJ (1989) Ciclosporin in the treatment of lupus nephritis. Am J Nephrol 9:57\u201360","journal-title":"Am J Nephrol"},{"key":"8582_CR74","first-page":"160","volume":"40","author":"MM Hussein","year":"1993","unstructured":"Hussein MM, Mooij JM, Roujouleh H (1993) Cyclosporine in the treatment of lupus nephritis including two patients treated during pregnancy. Clin Nephrol 40:160\u2013163","journal-title":"Clin Nephrol"},{"key":"8582_CR75","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/rheumatology\/35.7.669","volume":"35","author":"K Manger","year":"1996","unstructured":"Manger K, Kalden JR, Manger B (1996) Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 35:669\u2013675","journal-title":"Br J Rheumatol"},{"key":"8582_CR76","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/qjmed\/91.8.573","volume":"91","author":"LS Tam","year":"1998","unstructured":"Tam LS, Li EK, Leung CB, Wong KC, Lai FM, Wang A, Szeto CC, Lui SF (1998) Long-term treatment of lupus nephritis with cyclosporin A. QJM 91:573\u2013580","journal-title":"QJM"},{"key":"8582_CR77","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000101448","volume":"30","author":"Z Rihova","year":"2007","unstructured":"Rihova Z, Vankova Z, Maixnerova D, Dostal C, Jancova E, Honsova E, Merta M, Rysava R, Tesar V (2007) Treatment of lupus nephritis with cyclosporine - an outcome analysis. Kidney Blood Press Res 30:124\u20138","journal-title":"Kidney Blood Press Res"},{"key":"8582_CR78","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/s10165-006-0545-8","volume":"17","author":"H Ogawa","year":"2007","unstructured":"Ogawa H, Kameda H, Nagasawa H, Sekiguchi N, Takei H, Tsuzaka K, Amano K, Takeuchi T (2007) Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Mod Rheumatol 17:92\u201397","journal-title":"Mod Rheumatol"},{"key":"8582_CR79","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/0961203309350320","volume":"19","author":"H Ogawa","year":"2010","unstructured":"Ogawa H, Kameda H, Amano K, Takeuchi T (2010) Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus 19:162\u2013169","journal-title":"Lupus"},{"key":"8582_CR80","doi-asserted-by":"publisher","first-page":"136","DOI":"10.5414\/CN106920","volume":"76","author":"Y Kamijo","year":"2011","unstructured":"Kamijo Y, Hashimoto K, Takahashi K, Ehara T, Shigematsu H, Higuchi M (2011) Treatment with cyclosporine A improves SLE disease activity of Japanese patients with diffuse proliferative lupus nephritis. Clin Nephrol 76:136\u2013143","journal-title":"Clin Nephrol"},{"key":"8582_CR81","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000421703","volume":"99","author":"M Balletta","year":"1992","unstructured":"Balletta M, Sabella D, Magri P, Sepe V, Stanziale P, Di Luccio R, Colucci G, Fuiano G (1992) Ciclosporin plus steroids versus steroids alone in the treatment of lupus nephritis. Contrib Nephrol 99:129\u2013130","journal-title":"Contrib Nephrol"},{"key":"8582_CR82","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2215\/CJN.02271205","volume":"1","author":"G Moroni","year":"2006","unstructured":"Moroni G, Doria A, Mosca M, Alberighi OD, Ferraccioli G, Todesco S, Manno C, Altieri P, Ferrara R, Greco S, Ponticelli C (2006) A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 1:925\u2013932","journal-title":"Clin J Am Soc Nephrol"},{"key":"8582_CR83","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1177\/0961203310371155","volume":"19","author":"J Zavada","year":"2010","unstructured":"Zavada J, Pesickova S, Rysava R, Olejarova M, Hor\u00e1k P, Hrnc\u00edr Z, Rychl\u00edk I, Havrda M, V\u00edtova J, Luk\u00e1c J, Rovensky J, Tegzova D, B\u00f6hmova J, Zadrazil J, H\u00e1na J, Dost\u00e1l C, Tesar V (2010) Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 19:1281\u20139","journal-title":"Lupus"},{"key":"8582_CR84","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1177\/0961203313511555","volume":"23","author":"J Zavada","year":"2013","unstructured":"Zavada J, Pesickova SS, Rysava R, Hor\u00e1k P, Hrnc\u00edr Z, Luk\u00e1c J, Rovensky J, V\u00edtov\u00e1 J, Havrda M, Rychl\u00edk I, B\u00f6hmova J, Vlas\u00e1kov\u00e1 V, Slatinsk\u00e1 J, Zadrazil J, Olej\u00e1rov\u00e1 M, Tegzova D, Tesar V (2013) Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A. Lupus 23:69\u201374","journal-title":"Lupus"},{"key":"8582_CR85","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ndt\/gfn565","volume":"24","author":"G Moroni","year":"2009","unstructured":"Moroni G, Doria A, Ponticelli C (2009) Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant 24:15\u201320","journal-title":"Nephrol Dial Transplant"},{"key":"8582_CR86","first-page":"147","volume":"42","author":"J Radhakrishnan","year":"1994","unstructured":"Radhakrishnan J, Kunis CL, D\u2019Agati V, Appel GB (1994) Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 42:147\u2013154","journal-title":"Clin Nephrol"},{"key":"8582_CR87","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1191\/096120300680198935","volume":"9","author":"D Hallegua","year":"2000","unstructured":"Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR (2000) Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 9:241\u2013251","journal-title":"Lupus"},{"key":"8582_CR88","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1177\/096120330101001113","volume":"10","author":"LS Tam","year":"2001","unstructured":"Tam LS, Li EK, Szeto CC, Wong SM, Leung CB, Lai FM, Wong KC, Lui SF (2001) Treatment of membranous lupus nephritis with prednisone, azathioprine and cyclosporin A. Lupus 10:827\u2013829","journal-title":"Lupus"},{"key":"8582_CR89","first-page":"1827","volume":"116","author":"W Hu","year":"2003","unstructured":"Hu W, Liu Z, Shen S, Li S, Yao X, Chen H, Li L (2003) Cyclosporine A in treatment of membranous lupus nephropathy. Chin Med J 116:1827\u20131830","journal-title":"Chin Med J"},{"key":"8582_CR90","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1681\/ASN.2008060665","volume":"20","author":"HA Austin","year":"2009","unstructured":"Austin HA, Illei GG, Braun MJ, Balow JE (2009) Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20:901\u2013911","journal-title":"J Am Soc Nephrol"},{"key":"8582_CR91","first-page":"1","volume":"2014","author":"M Yang","year":"2014","unstructured":"Yang M, Li M, He W, Wang B, Gu Y (2014) Calcineurin inhibitors may be a reasonable alternative to cyclophosphamide in the induction treatment of active lupus nephritis: a systematic review and meta-analysis. Exp Ther Med 2014:1\u20138","journal-title":"Exp Ther Med"},{"key":"8582_CR92","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10067-014-2802-0","volume":"34","author":"SS Shaharir","year":"2015","unstructured":"Shaharir SS, Mustafar R, Mohd R, Mohd Said MS, Gafor HA (2015) Persistent hypertension in lupus nephritis and the associated risk factors. Clin Rheumatol 34:93\u201397","journal-title":"Clin Rheumatol"},{"key":"8582_CR93","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1191\/0961203306lu2266oa","volume":"15","author":"L Quartuccio","year":"2006","unstructured":"Quartuccio L, Sacco S, Franzolini N, Perin A, Ferraccioli G, De Vita S (2006) Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus. Lupus 15:76\u201379","journal-title":"Lupus"},{"key":"8582_CR94","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1191\/096120398678919660","volume":"7","author":"M Sugiyama","year":"1998","unstructured":"Sugiyama M, Ogasawara H, Kaneko H, Hishikawa T, Sekigawa I, Iida N, Hashimoto H, Hirose S (1998) Effect of extremely low dose cyclosporine treatment on the thrombocytopenia in systemic lupus erythematosus. Lupus 7:53\u20136","journal-title":"Lupus"},{"key":"8582_CR95","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1191\/0961203305lu2090cr","volume":"14","author":"SW Wang","year":"2005","unstructured":"Wang SW, Cheng TT (2005) Systemic lupus erythematosus with refractory hemolytic anemia effectively treated with cyclosporin A: a case report. Lupus 14:483\u2013485","journal-title":"Lupus"},{"key":"8582_CR96","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00296-003-0318-z","volume":"24","author":"NP Singh","year":"2004","unstructured":"Singh NP, Prakash A, Garg D, Makhija A, Pathania A, Prakash N, Kubba S, Agarwal SK (2004) Aplastic anemia complicating systemic lupus erythematosus: successful management with cyclosporine. Rheumatol Int 24:40\u201342","journal-title":"Rheumatol Int"},{"key":"8582_CR97","first-page":"759","volume":"21","author":"F Atzeni","year":"2003","unstructured":"Atzeni F, Sarzi-Puttini P, Capsoni F, Vulpio L, Carrabba M (2003) Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A. Clin Exp Rheumatol 21:759\u201362","journal-title":"Clin Exp Rheumatol"},{"key":"8582_CR98","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/rheumatology\/39.10.1155","volume":"39","author":"C Duarte-Salazar","year":"2000","unstructured":"Duarte-Salazar C, Cazar\u00edn-Barrientos J, Goycochea-Robles MV, Collazo-Jaloma J, Burgos-Vargas R (2000) Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with cyclosporin A. Rheumatology (Oxford) 39:1155\u20137","journal-title":"Rheumatology (Oxford)"},{"key":"8582_CR99","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/ajh.20237","volume":"78","author":"MO Arcasoy","year":"2005","unstructured":"Arcasoy MO, Chao NJ (2005) T-cell-mediated pure red-cell aplasia in systemic lupus erythematosus: response to cyclosporin A and mycophenolate mofetil. Am J Hematol 78:161\u20133","journal-title":"Am J Hematol"},{"key":"8582_CR100","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1177\/0961203314559086","volume":"24","author":"H Takahashi","year":"2015","unstructured":"Takahashi H, Tsuboi H, Kurata I, Takahashi H, Inoue S, Ebe H, Yokosawa M, Hagiwara S, Hirota T, Asashima H, Kaneko S, Kawaguchi H, Kurashima Y, Miki H, Umeda N, Kondo Y, Ogishima H, Suzuki T, Matsumoto I, Sumida T (2015) Predictors of the response to treatment in acute lupus hemophagocytic syndrome. Lupus 24:659\u2013668","journal-title":"Lupus"},{"key":"8582_CR101","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1365-2230.1995.tb01315.x","volume":"20","author":"S Grabbe","year":"1995","unstructured":"Grabbe S, Kolde G (1995) Coexisting lichen planus and subacute cutaneous lupus erythematosus. Clin Exp Dermatol 20:249\u2013254","journal-title":"Clin Exp Dermatol"},{"key":"8582_CR102","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1191\/096120300678828406","volume":"9","author":"Y Saeki","year":"2000","unstructured":"Saeki Y, Ohshima S, Kurimoto I, Miura H, Suemura M (2000) Maintaining remission of lupus erythematosus profundus (LEP) with cyclosporin A. Lupus 9:390\u2013392","journal-title":"Lupus"},{"key":"8582_CR103","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1001\/archderm.1986.01660210021007","volume":"122","author":"F Heule","year":"1986","unstructured":"Heule F, van Joost T, Beukers R (1986) Cyclosporine in the treatment of lupus erythematosus. Arch Dermatol 122:973\u2013974","journal-title":"Arch Dermatol"},{"key":"8582_CR104","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/j.1365-2133.1994.tb08471.x","volume":"131","author":"JA Yell","year":"1994","unstructured":"Yell JA, Burge SM (1994) Cyclosporin and discoid lupus erythematosus. Br J Dermatol 131:132\u2013133","journal-title":"Br J Dermatol"},{"key":"8582_CR105","doi-asserted-by":"publisher","first-page":"23597","DOI":"10.1074\/jbc.272.38.23597","volume":"272","author":"A Alevizopoulos","year":"1997","unstructured":"Alevizopoulos A, Dusserre Y, R\u00fcegg U, Mermod N (1997) Regulation of the transforming growth factor beta-responsive transcription factor CTF-1 by calcineurin and calcium\/calmodulin-dependent protein kinase IV. J Biol Chem 272:23597\u201323605","journal-title":"J Biol Chem"},{"key":"8582_CR106","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/0923-1811(95)00480-7","volume":"12","author":"T Karashima","year":"1996","unstructured":"Karashima T, Hachisuka H, Sasai Y (1996) FK506 and cyclosporin A inhibit growth factor-stimulated human keratinocyte proliferation by blocking cells in the G0\/G1 phases of the cell cycle. J Dermatol Sci 12:246\u2013254","journal-title":"J Dermatol Sci"},{"key":"8582_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2230.1988.tb00637.x","volume":"13","author":"C Frances","year":"1988","unstructured":"Frances C, Branchet MC, Bl\u00e9try O, Lefevre C, Boisnic S, Kern P, Godeau P (1988) Skin collagen from scleroderma patients before and after cyclosporin A treatment. Clin Exp Dermatol 13:1\u20133","journal-title":"Clin Exp Dermatol"},{"key":"8582_CR108","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/art.1780360113","volume":"36","author":"PJ Clements","year":"1993","unstructured":"Clements PJ, Lachenbruch PA, Sterz M, Danovitch G, Hawkins R, Ippoliti A, Paulus HE (1993) Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 36:75\u201383","journal-title":"Arthritis Rheum"},{"key":"8582_CR109","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1365-2133.1990.tb07290.x","volume":"122","author":"H Zachariae","year":"1990","unstructured":"Zachariae H, Halkier-S\u00f8rensen L, Heickendorff L, Zachariae E, Hansen HE (1990) Cyclosporin A treatment of systemic sclerosis. Br J Dermatol 122:677\u2013681","journal-title":"Br J Dermatol"},{"key":"8582_CR110","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1468-3083.2004.00717.x","volume":"18","author":"B Roch","year":"2004","unstructured":"Roch B, Wollina U, Schroeder H-E (2004) Long-term cyclosporin A in systemic sclerosis. J Eur Acad Dermatol Venereol 18:235\u2013236","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"8582_CR111","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/rheumatology\/38.10.992","volume":"38","author":"G Filaci","year":"1999","unstructured":"Filaci G, Cutolo M, Scudeletti M, Castagneto C, Derchi L, Gianrossi R, Ropolo F, Zentilin P, Sulli A, Murdaca G, Ghio M, Indiveri F, Puppo F (1999) Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12\u00a0months of therapy. Rheumatology (Oxford) 38:992\u2013996","journal-title":"Rheumatology (Oxford)"},{"key":"8582_CR112","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/art.1780370225","volume":"37","author":"P Zentilin","year":"1994","unstructured":"Zentilin P, Savarino V, Puppo F, Scudeletti M, Indiveri F (1994) Improvement in esophageal motor abnormalities in systemic sclerosis patients treated with cyclosporine: comment on the article by Clements et al. Arthritis Rheum 37:301\u2013302","journal-title":"Arthritis Rheum"},{"key":"8582_CR113","first-page":"191","volume":"31","author":"K Ando","year":"2013","unstructured":"Ando K, Nakashita T, Kaneko N, Takahashi K, Motojima S (2013) Long-term efficacy and safety of maintenance therapy with azathioprine or cyclosporine for interstitial lung disease with diffuse cutaneous scleroderma. Clin Exp Rheumatol 31:191\u2013192","journal-title":"Clin Exp Rheumatol"},{"key":"8582_CR114","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.3899\/jrheum.101262","volume":"38","author":"KM Walker","year":"2011","unstructured":"Walker KM, Pope J, Scleroderma Clinical Trials Consortium, Canadian Scleroderma Research Group (2011) Expert agreement on EULAR\/EUSTAR recommendations for the management of systemic sclerosis. J Rheumatol 38:1326\u20131328","journal-title":"J Rheumatol"},{"key":"8582_CR115","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/rheumatology\/33.1.90","volume":"33","author":"CP Denton","year":"1994","unstructured":"Denton CP, Sweny P, Abdulla A, Black CM (1994) Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 33:90\u201392","journal-title":"Br J Rheumatol"},{"key":"8582_CR116","first-page":"381","volume":"21","author":"JM Grau","year":"1994","unstructured":"Grau JM, Herrero C, Casademont J, Fern\u00e1ndez-Sol\u00e0 J, Urbano-M\u00e1rquez A (1994) Cyclosporine A as first choice therapy for dermatomyositis. J Rheumatol 21:381\u2013382","journal-title":"J Rheumatol"},{"key":"8582_CR117","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/030097400750001897","volume":"29","author":"J Vencovsk\u00fd","year":"2000","unstructured":"Vencovsk\u00fd J, Jarosov\u00e1 K, Mach\u00e1cek S, Stud\u00fdnkov\u00e1 J, Kafkov\u00e1 J, Bart\u016fnkov\u00e1 J, Nemcov\u00e1 D, Charv\u00e1t F (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29:95\u2013102","journal-title":"Scand J Rheumatol"},{"key":"8582_CR118","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00296-006-0168-6","volume":"27","author":"S Mii","year":"2006","unstructured":"Mii S, Niiyama S, Kusunoki M, Arai S, Katsuoka K (2006) Cyclosporine A as treatment of esophageal involvement in dermatomyositis. Rheumatol Int 27:183\u2013185","journal-title":"Rheumatol Int"},{"key":"8582_CR119","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2177\/jsci.28.148","volume":"28","author":"T Kotani","year":"2005","unstructured":"Kotani T, Makino S, Kawasaki Y, Hirano S, Tabushi Y, Kagitani M, Takeuchi T, Hanafusa T (2005) A case of interstitial pneumonia associated with dermatomyositis effectively treated with cyclosporin-A and cyclophosphamide pulse. Nihon Rinsho Meneki Gakkai Kaishi 28:148\u2013153","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"8582_CR120","first-page":"254","volume":"35","author":"T Kotani","year":"2008","unstructured":"Kotani T, Makino S, Takeuchi T, Kagitani M, Shoda T, Hata A, Tabushi Y, Hanafusa T (2008) Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute\/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 35:254\u2013259","journal-title":"J Rheumatol"},{"key":"8582_CR121","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3109\/s10165-006-0556-5","volume":"17","author":"M Terao","year":"2007","unstructured":"Terao M, Ozawa K, Inui S, Murota H, Yokomi A, Itami S (2007) A case of dermatomyositis complicated with pneumomediastinum. Mod Rheumatol 17:156\u2013159","journal-title":"Mod Rheumatol"},{"key":"8582_CR122","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/08916930500124023","volume":"38","author":"K Takada","year":"2005","unstructured":"Takada K, Nagasaka K, Miyasaka N (2005) Polymyositis\/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 38:383\u2013392","journal-title":"Autoimmunity"},{"key":"8582_CR123","first-page":"436","volume":"31","author":"A Labirua-Iturburu","year":"2013","unstructured":"Labirua-Iturburu A, Selva-O\u2019Callaghan A, Mart\u00ednez-G\u00f3mez X, Trallero-Aragu\u00e1s E, Labrador-Horrillo M, Vilardell-Tarr\u00e9s M (2013) Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol 31:436\u2013439","journal-title":"Clin Exp Rheumatol"},{"key":"8582_CR124","first-page":"171","volume":"43","author":"S Sakamoto","year":"2005","unstructured":"Sakamoto S, Homma S, Kawabat M, Kono T, Motoi N, Yoshimur K (2005) A case of corticosteroid-resistant nonspecific interstitial pneumonia associated with dermatomyositis successfully treated with cyclosporin A. Nihon Kokyuki Gakkai Zasshi 43:171\u2013178","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"8582_CR125","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3899\/jrheum.121026","volume":"40","author":"L Cavagna","year":"2013","unstructured":"Cavagna L, Caporali R, Abd\u00ec-Al\u00ec L, Dore R, Meloni F, Montecucco C (2013) Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol 40:484\u2013492","journal-title":"J Rheumatol"},{"key":"8582_CR126","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2177\/jsci.36.122","volume":"36","author":"A Suzuki","year":"2013","unstructured":"Suzuki A, Shoji N, Kikuchi E, Uekubo K, Aoki N, Sonoda Y, Torigai H, Yamashita H, Fujita K, Okai T (2013) Successful combination therapy with corticosteroids, biweekly intravenous pulse cyclophosphamide and cyclosporin A for acute interstitial pneumonia in patients with dermatomyositis: report of three cases. Nihon Rinsho Meneki Gakkai Kaishi 36:122\u2013128","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"8582_CR127","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.autrev.2011.09.007","volume":"11","author":"F Ingegnoli","year":"2012","unstructured":"Ingegnoli F, Lubatti C, Ingegnoli A, Boracchi P, Zeni S, Meroni PL (2012) Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev 11:335\u2013340","journal-title":"Autoimmun Rev"},{"key":"8582_CR128","doi-asserted-by":"publisher","first-page":"491","DOI":"10.7326\/0003-4819-108-3-491_1","volume":"108","author":"F Gremmel","year":"1988","unstructured":"Gremmel F, Druml W, Schmidt P, Graninger W (1988) Cyclosporin in Wegener granulomatosis. Ann Intern Med 108:491","journal-title":"Ann Intern Med"},{"key":"8582_CR129","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1136\/ard.49.7.568-a","volume":"49","author":"JC Borleffs","year":"1990","unstructured":"Borleffs JC, van der Zwan JC (1990) Cyclosporin in Wegener\u2019s granulomatosis with renal failure. Ann Rheum Dis 49:568","journal-title":"Ann Rheum Dis"},{"key":"8582_CR130","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1445-5994.1990.tb00376.x","volume":"20","author":"N Harley","year":"1990","unstructured":"Harley N, Ihle B (1990) Wegener\u2019s granulomatosis\u2014use of cyclosporin-A: a case report. Aust N Z J Med 20:71\u201373","journal-title":"Aust N Z J Med"},{"key":"8582_CR131","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/archinte.160.3.393","volume":"160","author":"K Inoue","year":"2000","unstructured":"Inoue K, Kondo M, Inoue M, Ishino H, Kamitsuji Y, Sano H (2000) Successful treatment with combination therapy of cyclophosphamide and cyclosporin for late recurrence of Wegener granulomatosis. Arch Intern Med 160:393\u2013394","journal-title":"Arch Intern Med"},{"key":"8582_CR132","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1136\/ard.57.4.258a","volume":"57","author":"EM McDermott","year":"1998","unstructured":"McDermott EM, Powell RJ (1998) Cyclosporin in the treatment of Churg-Strauss syndrome. Ann Rheum Dis 57:258\u2013259","journal-title":"Ann Rheum Dis"},{"key":"8582_CR133","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/rheumatology\/37.4.464","volume":"37","author":"C Schaufelberger","year":"1998","unstructured":"Schaufelberger C, Andersson R, Nordborg E (1998) No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study. Br J Rheumatol 37:464\u20135","journal-title":"Br J Rheumatol"},{"key":"8582_CR134","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/art.1780280921","volume":"28","author":"D Wendling","year":"1985","unstructured":"Wendling D, Hory B, Blanc D (1985) Cyclosporine: a new adjuvant therapy for giant cell arteritis? Arthritis Rheum 28:1078\u20131079","journal-title":"Arthritis Rheum"},{"key":"8582_CR135","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/03009740500474537","volume":"35","author":"C Schaufelberger","year":"2006","unstructured":"Schaufelberger C, M\u00f6llby H, Uddhammar A, Bratt J, Nordborg E (2006) No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol 35:327\u2013329","journal-title":"Scand J Rheumatol"},{"key":"8582_CR136","doi-asserted-by":"crossref","first-page":"566","DOI":"10.5694\/j.1326-5377.1999.tb127892.x","volume":"170","author":"H Horigome","year":"1999","unstructured":"Horigome H, Kamoda T, Matsui A (1999) Treatment of glucocorticoid-dependent Takayasu\u2019s arteritis with cyclosporin. Med J Aust 170:566","journal-title":"Med J Aust"},{"key":"8582_CR137","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1046\/j.1365-2133.1999.02989.x","volume":"141","author":"LA Fearfield","year":"1999","unstructured":"Fearfield LA, Ross JR, Farrell AM, Costello C, Bunker CB, Staughton RC (1999) Pyoderma gangrenosum associated with Takayasu\u2019s arteritis responding to cyclosporin. Br J Dermatol 141:339\u2013343","journal-title":"Br J Dermatol"},{"key":"8582_CR138","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1001\/archderm.1991.01680100135027","volume":"127","author":"SH Fullerton","year":"1991","unstructured":"Fullerton SH, Abel EA, Getz K, el-Ramahi K (1991) Cyclosporine treatment of severe recalcitrant pyoderma gangrenosum in a patient with Takayasu\u2019s arteritis. Arch Dermatol 127:1731\u20131732","journal-title":"Arch Dermatol"},{"key":"8582_CR139","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.1780240111","volume":"24","author":"P de Merieux","year":"1981","unstructured":"de Merieux P, Spitler LE, Paulus HE (1981) Treatment of Behcet\u2019s syndrome with levamisole. Arthritis Rheum 24:64\u201370","journal-title":"Arthritis Rheum"},{"key":"8582_CR140","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"G Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, K\u00f6tter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, St\u00fcbiger N, Yurdakul S, Yazici H (2008) EULAR recommendations for the management of Beh\u00e7et disease. Ann Rheum Dis 67:1656\u20131662","journal-title":"Ann Rheum Dis"},{"key":"8582_CR141","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/bjo.76.4.241","volume":"76","author":"Y Ozyazgan","year":"1992","unstructured":"Ozyazgan Y, Yurdakul S, Yazici H, \u00fcz\u00fcn B, I\u015f\u00e7imen A, T\u00fcz\u00fcn Y, Aktun\u00e7 T, Pazarli H, Hamuryudan V, M\u00fcft\u00fco\u011flu A (1992) Low dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et\u2019s syndrome: a single masked trial. Br J Ophthalmol 76:241\u2013243","journal-title":"Br J Ophthalmol"},{"key":"8582_CR142","first-page":"136","volume":"20","author":"D BenEzra","year":"1988","unstructured":"BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, de Courten C, Harris W (1988) Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et\u2019s syndrome. Transplant Proc 20:136\u2013143","journal-title":"Transplant Proc"},{"key":"8582_CR143","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","volume":"1","author":"K Masuda","year":"1989","unstructured":"Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G (1989) Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et\u2019s disease. Lancet 1:1093\u20131096","journal-title":"Lancet"},{"key":"8582_CR144","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/bjo.2009.158840","volume":"94","author":"Y Yamada","year":"2010","unstructured":"Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M (2010) Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 94:284\u2013288","journal-title":"Br J Ophthalmol"},{"key":"8582_CR145","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000060761","volume":"31","author":"H Yazici","year":"1999","unstructured":"Yazici H, Ozyazgan Y (1999) Medical management of Beh\u00e7et\u2019s syndrome. Dev Ophthalmol 31:118\u2013131","journal-title":"Dev Ophthalmol"},{"key":"8582_CR146","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1365-4362.1997.tb03133.x","volume":"36","author":"T Ergun","year":"1997","unstructured":"Ergun T, G\u00fcrb\u00fcz O, Yurdakul S, Hamuryudan V, Bekiro\u011flu N, Yazici H (1997) Topical cyclosporine-A for treatment of oral ulcers of Beh\u00e7et\u2019s syndrome. Int J Dermatol 36:720","journal-title":"Int J Dermatol"},{"key":"8582_CR147","first-page":"391","volume":"17","author":"F Cantini","year":"1999","unstructured":"Cantini F, Salvarani C, Niccoli L, Padula A, Arena AI, Bellandi F, Macchioni P, Olivieri I (1999) Treatment of thrombophlebitis of Beh\u00e7et\u2019s disease with low dose cyclosporin A. Clin Exp Rheumatol 17:391\u2013392","journal-title":"Clin Exp Rheumatol"},{"key":"8582_CR148","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0190-9622(97)80354-4","volume":"36","author":"O Avci","year":"1997","unstructured":"Avci O, G\u00fcrler N, G\u00fcne\u015f AT (1997) Efficacy of cyclosporine on mucocutaneous manifestations of Beh\u00e7et\u2019s disease. J Am Acad Dermatol 36:796\u2013797","journal-title":"J Am Acad Dermatol"},{"key":"8582_CR149","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","volume":"106","author":"S Kotake","year":"1999","unstructured":"Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H (1999) Central nervous system symptoms in patients with Beh\u00e7et disease receiving cyclosporine therapy. Ophthalmology 106:586\u2013589","journal-title":"Ophthalmology"},{"key":"8582_CR150","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","volume":"25","author":"I K\u00f6tter","year":"2005","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Batra M, Vonthein R, St\u00fcbiger N, Fierlbeck G, Melms A (2005) CNS involvement occurs more frequently in patients with Beh\u00e7et\u2019s disease under cyclosporin A (CSA) than under other medications\u2014results of a retrospective analysis of 117 cases. Clin Rheumatol 25:482\u2013486","journal-title":"Clin Rheumatol"},{"key":"8582_CR151","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1046\/j.1442-9071.2001.00445.x","volume":"29","author":"Y Kato","year":"2001","unstructured":"Kato Y, Numaga J, Kato S, Kaburaki T, Kawashima H, Fujino Y (2001) Central nervous system symptoms in a population of Beh\u00e7et\u2019s disease patients with refractory uveitis treated with cyclosporine A. Clin Exp Ophthalmol 29:335\u2013336","journal-title":"Clin Exp Ophthalmol"},{"key":"8582_CR152","first-page":"33","volume":"11","author":"Y Jamilloux","year":"2015","unstructured":"Jamilloux Y, Gerfaud-Valentin M, Henry T, S\u00e8ve P (2015) Treatment of adult-onset Still\u2019s disease: a review. Ther Clin Risk Manag 11:33\u201343","journal-title":"Ther Clin Risk Manag"},{"key":"8582_CR153","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/s10165-008-0126-0","volume":"19","author":"M Mitamura","year":"2009","unstructured":"Mitamura M, Tada Y, Koarada S, Noue H, Suematsu R, Ohta A, Nagasawa K (2009) Cyclosporin A treatment for Japanese patients with severe adult-onset Still\u2019s disease. Mod Rheumatol 19:57\u201363","journal-title":"Mod Rheumatol"},{"key":"8582_CR154","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10067-014-2487-4","volume":"33","author":"P Efthimiou","year":"2014","unstructured":"Efthimiou P, Kadavath S, Mehta B (2014) Life-threatening complications of adult-onset Still\u2019s disease. Clin Rheumatol 33:305\u2013314","journal-title":"Clin Rheumatol"},{"key":"8582_CR155","first-page":"147","volume":"34","author":"T Mori","year":"1993","unstructured":"Mori T, Tanigawa M, Iwasaki E, Tamaki S, Ono T, Wada H, Deguchi K, Shirakawa S (1993) Cyclosporine therapy of adult onset Still\u2019s disease with disseminated intravascular coagulation. Rinsho Ketsueki 34:147\u2013152","journal-title":"Rinsho Ketsueki"},{"key":"8582_CR156","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3346\/jkms.2004.19.1.137","volume":"19","author":"J-H Park","year":"2004","unstructured":"Park J-H, Bae JH, Choi Y-S, Lee HS, Jun JB, Jung S, Yoo DH, Bae SC, Kim TH (2004) Adult-onset Still\u2019s disease with disseminated intravascular coagulation and multiple organ dysfunctions dramatically treated with cyclosporine A. J Korean Med Sci 19:137\u2013141","journal-title":"J Korean Med Sci"},{"key":"8582_CR157","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/S0755-4982(05)84239-3","volume":"34","author":"M Hamidou","year":"2005","unstructured":"Hamidou M, Boutoille D, Masseau A, Garand R, Raffi F (2005) Adult-onset Still disease with hemophagocytic syndrome treated with cyclosporine. Presse Med 34:1634\u20131636","journal-title":"Presse Med"},{"key":"8582_CR158","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1752-1947-3-138","volume":"3","author":"M Mizrahi","year":"2009","unstructured":"Mizrahi M, Ben-Chetrit E (2009) Relapsing macrophage activating syndrome in a 15-year-old girl with Still\u2019s disease: a case report. J Med Case Rep 3:138","journal-title":"J Med Case Rep"},{"key":"8582_CR159","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00296-006-0202-8","volume":"27","author":"M-Y Her","year":"2007","unstructured":"Her M-Y, Kim T-H, Chang H-K, Lee W-S, Yoo D-H (2007) Successful treatment of acquired amegakaryocytic thrombocytopenia with cyclosporine in adult onset Still\u2019s disease. Rheumatol Int 27:295\u2013298","journal-title":"Rheumatol Int"},{"key":"8582_CR160","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s10067-008-0950-9","volume":"27","author":"T Nagashima","year":"2008","unstructured":"Nagashima T, Aoki Y, Onishi S, Iwamoto M, Okazaki H, Minota S (2008) Steroid-refractory severe hepatic failure in adult onset Still\u2019s disease responding to cyclosporine. Clin Rheumatol 27:1451\u20131453","journal-title":"Clin Rheumatol"},{"key":"8582_CR161","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/archopht.120.3.330","volume":"120","author":"KS Kunert","year":"2002","unstructured":"Kunert KS, Tisdale AS, Gipson IK (2002) Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 120:330\u2013337","journal-title":"Arch Ophthalmol"},{"key":"8582_CR162","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","volume":"118","author":"KS Kunert","year":"2000","unstructured":"Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK (2000) Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol 118:1489\u20131496","journal-title":"Arch Ophthalmol"},{"key":"8582_CR163","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/ICO.0b013e318158f6dc","volume":"27","author":"SC Pflugfelder","year":"2008","unstructured":"Pflugfelder SC, De Paiva CS, Villarreal AL, Stern ME (2008) Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production. Cornea 27:64\u201369","journal-title":"Cornea"},{"key":"8582_CR164","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/01.iio.0000212135.77675.6a","volume":"46","author":"GN Foulks","year":"2006","unstructured":"Foulks GN (2006) Topical cyclosporine for treatment of ocular surface disease. Int Ophthalmol Clin 46:105\u2013122","journal-title":"Int Ophthalmol Clin"},{"key":"8582_CR165","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","volume":"7","author":"D Stevenson","year":"2000","unstructured":"Stevenson D, Tauber J, Reis BL (2000) Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 7:967\u2013974","journal-title":"Ophthalmology"},{"key":"8582_CR166","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.ophtha.2005.05.013","volume":"112","author":"LD Barber","year":"2005","unstructured":"Barber LD, Pflugfelder SC, Tauber J, Foulks GN (2005) Phase III safety evaluation of cyclosporine 0.1\u00a0% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3\u00a0years. Ophthalmology 112:1790\u20131794","journal-title":"Ophthalmology"},{"key":"8582_CR167","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","volume":"107","author":"K Sall","year":"2000","unstructured":"Sall K, Stevenson OD, Mundorf TK, Reis BL (2000) Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 107:631\u2013639","journal-title":"Ophthalmology"},{"key":"8582_CR168","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/ICO.0b013e318074e460","volume":"26","author":"CW Roberts","year":"2007","unstructured":"Roberts CW, Carniglia PE, Brazzo BG (2007) Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye. Cornea 26:805\u2013809","journal-title":"Cornea"},{"key":"8582_CR169","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ajo.2008.08.015","volume":"147","author":"EC Kim","year":"2009","unstructured":"Kim EC, Choi J-S, Joo C-K (2009) A comparison of vitamin a and cyclosporine a 0.05\u00a0% eye drops for treatment of dry eye syndrome. Am J Ophthalmol 147:206\u2013213.e3","journal-title":"Am J Ophthalmol"},{"key":"8582_CR170","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/ard.45.9.732","volume":"45","author":"AA Drosos","year":"1986","unstructured":"Drosos AA, Skopouli FN, Costopoulos JS, Papadimitriou CS, Moutsopoulos HM (1986) Cyclosporin A (CyA) in primary Sj\u00f6gren\u2019s syndrome: a double blind study. Ann Rheum Dis 45:732\u2013735","journal-title":"Ann Rheum Dis"},{"key":"8582_CR171","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/15027732.1986.12461421","volume":"61","author":"AA Drosos","year":"1986","unstructured":"Drosos AA, Skopouli FN, Galanopoulou VK, Kitridou RC, Moutsopoulos HM (1986) Cyclosporin a therapy in patients with primary Sj\u00f6gren\u2019s syndrome: results at one year. Scand J Rheumatol 61:246\u2013249","journal-title":"Scand J Rheumatol"},{"key":"8582_CR172","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S0140-6736(89)92456-2","volume":"8646","author":"J Heckmatt","year":"1989","unstructured":"Heckmatt J, Hasson N, Saunders C, Thompson N, Peters AM, Cambridge G, Rose M, Hyde SA, Dubowitz V (1989) Cyclosporin in juvenile dermatomyositis. Lancet 8646:1063\u20131066","journal-title":"Lancet"},{"key":"8582_CR173","first-page":"2436","volume":"24","author":"A Reiff","year":"1997","unstructured":"Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, Bernstein BH (1997) Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 24:2436\u20132443","journal-title":"J Rheumatol"},{"key":"8582_CR174","first-page":"203","volume":"11","author":"V Pistoia","year":"1993","unstructured":"Pistoia V, Buoncompagni A, Scribanis R, Fasce L, Alpigiani G, Cordone G, Ferrarini M, Borrone C, Cottafava F (1993) Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. Clin Exp Rheumatol 11:203\u2013208","journal-title":"Clin Exp Rheumatol"},{"key":"8582_CR175","doi-asserted-by":"publisher","first-page":"O19","DOI":"10.1186\/1546-0096-11-S2-O19","volume":"11","author":"N Ruperto","year":"2013","unstructured":"Ruperto N, Pistorio A, Knupp Feitosa de Oliveira S, Cuttica R, Ravelli A, Fischbach M et al (2013) A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate. Pediatr Rheumatol 11:O19","journal-title":"Pediatr Rheumatol"},{"key":"8582_CR176","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1002\/art.38092","volume":"65","author":"S Ringold","year":"2013","unstructured":"Ringold S, Weiss PF, Beukelman T, DeWitt EM, Ilowite NT, Kimura Y, Laxer RM, Lovell DJ, Nigrovic PA, Robinson AB, Vehe RK, American College of Rheumatology (2013) 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 65:2499\u20132512","journal-title":"Arthritis Rheum"},{"key":"8582_CR177","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/rheumatology\/40.8.907","volume":"40","author":"V Gerloni","year":"2001","unstructured":"Gerloni V, Cimaz R, Gattinara M, Arnoldi C, Pontikaki I, Fantini F (2001) Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology (Oxford) 40:907\u2013913","journal-title":"Rheumatology (Oxford)"},{"key":"8582_CR178","first-page":"1536","volume":"15","author":"M Ostensen","year":"1988","unstructured":"Ostensen M, H\u00f8yeraal HM, K\u00e5ss E (1988) Tolerance of cyclosporine A in children with 17refractory juvenile rheumatoid arthritis. J Rheumatol 15:1536\u20131538","journal-title":"J Rheumatol"},{"key":"8582_CR179","first-page":"569","volume":"20","author":"A Ravelli","year":"2002","unstructured":"Ravelli A, Moretti C, Temporini F, Rossi F, Magni-Manzoni S, Pistorio A, Martini A (2002) Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis. Clin Exp Rheumatol 20:569\u2013572","journal-title":"Clin Exp Rheumatol"},{"key":"8582_CR180","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0022-3476(96)70160-9","volume":"129","author":"R Mouy","year":"1996","unstructured":"Mouy R, Stephan JL, Pillet P, Haddad E, Hubert P, Prieur AM (1996) Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 129:750\u2013754","journal-title":"J Pediatr"},{"key":"8582_CR181","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0022-3476(96)70408-0","volume":"128","author":"A Ravelli","year":"1996","unstructured":"Ravelli A, De Benedetti F, Viola S, Martini A (1996) Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr 128:275\u2013278","journal-title":"J Pediatr"},{"key":"8582_CR182","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/rheumatology\/40.11.1285","volume":"40","author":"JL Stephan","year":"2001","unstructured":"Stephan JL, Kon\u00e9-Paut I, Galambrun C, Mouy R, Bader-Meunier B, Prieur AM (2001) Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 40:1285\u20131292","journal-title":"Rheumatology (Oxford)"},{"key":"8582_CR183","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1136\/adc.85.5.421","volume":"85","author":"S Sawhney","year":"2001","unstructured":"Sawhney S, Woo P, Murray KJ (2001) Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 85:421\u2013426","journal-title":"Arch Dis Child"},{"key":"8582_CR184","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000083450","volume":"113","author":"S Kounami","year":"2005","unstructured":"Kounami S, Yoshiyama M, Nakayama K, Okuda M, Okuda S, Aoyagi N, Yoshikawa N (2005) Macrophage activation syndrome in children with systemic-onset juvenile chronic arthritis. Acta Haematol 113:124\u2013129","journal-title":"Acta Haematol"},{"key":"8582_CR185","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/08035320600649713","volume":"95","author":"E Cortis","year":"2006","unstructured":"Cortis E, Insalaco A (2006) Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr 95:38\u201341","journal-title":"Acta Paediatr"},{"key":"8582_CR186","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3346\/jkms.2006.21.6.1124","volume":"21","author":"CR You","year":"2006","unstructured":"You CR, Kim HR, Yoon CH, Lee SH, Park SH, Kim HY (2006) Macrophage activation syndrome in juvenile rheumatoid arthritis successfully treated with cyclosporine A: a case report. J Korean Med Sci 21:1124\u20131127","journal-title":"J Korean Med Sci"},{"key":"8582_CR187","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s10067-012-1998-0","volume":"31","author":"CI Lin","year":"2012","unstructured":"Lin CI, Yu HH, Lee JH, Wang LC, Lin YT, Yang YH, Chiang BL (2012) Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol 31:1223\u20131230","journal-title":"Clin Rheumatol"},{"key":"8582_CR188","doi-asserted-by":"publisher","first-page":"4510","DOI":"10.1128\/JVI.80.9.4510-4520.2006","volume":"80","author":"N Ishii","year":"2006","unstructured":"Ishii N, Watashi K, Hishiki T, Goto K, Inoue D, Hijikata M, Wakita T, Kato N, Shimotohno K (2006) Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 80:4510\u20134520","journal-title":"J Virol"},{"key":"8582_CR189","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bbrc.2003.11.080","volume":"313","author":"M Nakagawa","year":"2004","unstructured":"Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, Kurosaki M, Maekawa S, Yamashiro T, Chen CH, Itsui Y, Kakinuma S, Watanabe M (2004) Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 313:42\u201347","journal-title":"Biochem Biophys Res Commun"},{"key":"8582_CR190","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.autrev.2008.07.009","volume":"8","author":"M Galeazzi","year":"2008","unstructured":"Galeazzi M, Giannitti C, Manganelli S, Benucci M, Scarpato S, Bazzani C, Caporali R, Sebastiani GD (2008) Treatment of rheumatic diseases in patients with HCV and HIV infection. Autoimmun Rev 8:100\u2013103","journal-title":"Autoimmun Rev"},{"key":"8582_CR191","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/j.1478-3231.2007.01560.x","volume":"27","author":"M Kohjima","year":"2007","unstructured":"Kohjima M, Enjoji M, Higuchi N, Kotoh K, Kato M, Takayanagi R, Nakamuta M (2007) NIM811, a nonimmunosuppressive cyclosporine analogue, suppresses collagen production and enhances collagenase activity in hepatic stellate cells. Liver Int 27:1273\u20131281","journal-title":"Liver Int"},{"key":"8582_CR192","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1196\/annals.1423.058","volume":"1110","author":"M Galeazzi","year":"2007","unstructured":"Galeazzi M, Bellisai F, Giannitti C, Manganelli S, Morozzi G, Sebastiani GD (2007) Safety of cyclosporin a in HCV-infected patients: experience with cyclosporin a in patients affected by rheumatological disorders and concomitant HCV infection. Ann N Y Acad Sci 1110:544\u2013549","journal-title":"Ann N Y Acad Sci"},{"key":"8582_CR193","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.autrev.2006.01.002","volume":"5","author":"M Galeazzi","year":"2006","unstructured":"Galeazzi M, Bellisai F, Manganelli S, Morozzi G, Sebastiani GD (2006) Cyclosporine A for the treatment of autoimmune disorders in HCV infected patients. Autoimmun Rev 5:493\u2013498","journal-title":"Autoimmun Rev"},{"key":"8582_CR194","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s10067-006-0412-1","volume":"26","author":"F Bellisai","year":"2006","unstructured":"Bellisai F, Giannitti C, Donvito A, Galeazzi M (2006) Combination therapy with cyclosporine A and anti-TNF-\u03b1 agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 26:1127\u20131129","journal-title":"Clin Rheumatol"},{"key":"8582_CR195","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1097\/01.ASN.0000139069.59466.D8","volume":"15","author":"A Tendron-Franzin","year":"2004","unstructured":"Tendron-Franzin A, Gouyon J-B, Guignard J-P, Decramer S, Justrabo E, Gilbert T, Semama DS (2004) Long-term effects of in utero exposure to cyclosporin A on renal function in the rabbit. J Am Soc Nephrol 15:2687\u20132693","journal-title":"J Am Soc Nephrol"},{"key":"8582_CR196","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1097\/00007890-200104270-00006","volume":"71","author":"B Bar Oz","year":"2001","unstructured":"Bar Oz B, Hackman R, Einarson T, Koren G (2001) Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 71:1051\u20131055","journal-title":"Transplantation"},{"key":"8582_CR197","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1517\/14740338.2014.951326","volume":"13","author":"M Gerosa","year":"2014","unstructured":"Gerosa M, Meroni PL, Cimaz R (2014) Safety considerations when prescribing immunosuppression medication to pregnant women. Expert Opin Drug Saf 13:1591\u20139","journal-title":"Expert Opin Drug Saf"},{"key":"8582_CR198","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0041-1345(98)01519-X","volume":"31","author":"CW Stanley","year":"1999","unstructured":"Stanley CW, Gottlieb R, Zager R, Eisenberg J, Richmond R, Moritz MJ, Armenti VT (1999) Developmental well-being in offspring of women receiving cyclosporine post-renal transplant. Transplant Proc 31:241\u20132","journal-title":"Transplant Proc"},{"key":"8582_CR199","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.toxlet.2003.12.030","volume":"149","author":"R Cimaz","year":"2004","unstructured":"Cimaz R, Meregalli E, Biggioggero M, Borghi O, Tincani A, Motta M, Air\u00f2 P, Meroni PL (2004) Alterations in the immune system of children from mothers treated with immunosuppressive agents during pregnancy. Toxicol Lett 149:155\u2013162","journal-title":"Toxicol Lett"},{"key":"8582_CR200","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1177\/0961203307079569","volume":"16","author":"M Biggioggero","year":"2007","unstructured":"Biggioggero M, Borghi MO, Gerosa M, Trespidi L, Cimaz R, Meroni PL (2007) Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants. Lupus 16:651\u2013656","journal-title":"Lupus"},{"key":"8582_CR201","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1097\/01.TP.0000066352.86763.D0","volume":"75","author":"ME Moretti","year":"2003","unstructured":"Moretti ME, Sgro M, Johnson DW, Sauve RS, Woolgar MJ, Taddio A, Verjee Z, Giesbrecht E, Koren G, Ito S (2003) Cyclosporine excretion into breast milk. Transplantation 75:2144\u20132146","journal-title":"Transplantation"},{"key":"8582_CR202","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/00007890-199801270-00019","volume":"65","author":"G Nyberg","year":"1998","unstructured":"Nyberg G, Haljam\u00e4e U, Frisenette-Fich C, Wennergren M, Kjellmer I (1998) Breast-feeding during treatment with cyclosporine. Transplantation 65:253\u2013255","journal-title":"Transplantation"},{"key":"8582_CR203","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1542\/peds.108.3.776","volume":"108","author":"American Academy of Pediatrics Committee on Drugs","year":"2001","unstructured":"American Academy of Pediatrics Committee on Drugs (2001) Transfer of drugs and other chemicals into human milk. Pediatrics 108:776\u2013789","journal-title":"Pediatrics"},{"key":"8582_CR204","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0950-3579(05)80309-7","volume":"9","author":"MJ Borigini","year":"1995","unstructured":"Borigini MJ, Paulus HE (1995) Innovative treatment approaches for rheumatoid arthritis. Combination therapy. Baillieres Clin Rheumatol 9:689\u2013710","journal-title":"Baillieres Clin Rheumatol"},{"key":"8582_CR205","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1191\/096120301672970034","volume":"10","author":"B Griffiths","year":"2001","unstructured":"Griffiths B, Emery P (2001) The treatment of lupus with cyclosporin A. Lupus 10:165\u2013170","journal-title":"Lupus"},{"key":"8582_CR206","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.jaad.2010.02.062","volume":"63","author":"C Ryan","year":"2010","unstructured":"Ryan C, Amor KT, Menter A (2010) The use of cyclosporine in dermatology: part II. J Am Acad Dermatol 63:949\u2013972","journal-title":"J Am Acad Dermatol"},{"key":"8582_CR207","unstructured":"U.S. Food and Drug Administration Web site. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050715s027,050716s028lbl.pdf"},{"key":"8582_CR208","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1002\/1529-0131(200008)43:8<1809::AID-ANR17>3.0.CO;2-D","volume":"43","author":"A Gough","year":"2000","unstructured":"Gough A, Helliwell P, Martin M, Huston G, Pease C, Veale DJ, Isaacs J, van der Heijde DM, Emery P (2000) Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 43:1809\u201319","journal-title":"Arthritis Rheum"},{"key":"8582_CR209","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1136\/ard.2008.091553","volume":"68","author":"V Bejarano","year":"2009","unstructured":"Bejarano V, Conaghan PG, Proudman SM, Buch MH, Brown AK, Emery P (2009) Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis. Ann Rheum Dis 68:761\u2013763","journal-title":"Ann Rheum Dis"},{"key":"8582_CR210","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1046\/j.1525-1594.2000.06623.x","volume":"24","author":"R Bambauer","year":"2000","unstructured":"Bambauer R, Schwarze U, Schiel R (2000) Cyclosporin A and therapeutic plasma exchange in the treatment of severe systemic lupus erythematosus. Artif Organs 24:852\u2013856","journal-title":"Artif Organs"},{"key":"8582_CR211","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1093\/rheumatology\/39.8.865","volume":"39","author":"SJ Morton","year":"2000","unstructured":"Morton SJ, Powell RJ (2000) Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology (Oxford) 39:865\u2013869","journal-title":"Rheumatology (Oxford)"},{"key":"8582_CR212","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s00296-008-0822-2","volume":"29","author":"H-J Kim","year":"2009","unstructured":"Kim H-J, Hong Y-K, Yoo W-H (2009) Dermatomyositis, complicated with pneumomediastinum, successfully treated with cyclosporine A: a case report and review of literature. Rheumatol Int 29:1101\u20131104","journal-title":"Rheumatol Int"},{"key":"8582_CR213","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10067-011-1713-6","volume":"30","author":"T Kotani","year":"2011","unstructured":"Kotani T, Takeuchi T, Makino S, Hata K, Yoshida S, Nagai K, Wakura D, Shoda T, Hanafusa T (2011) Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute\/subacute interstitial pneumonia. Clin Rheumatol 30:1021\u20131028","journal-title":"Clin Rheumatol"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-016-8582-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8582-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8582-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-016-8582-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T17:04:14Z","timestamp":1749056654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-016-8582-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,11]]},"references-count":213,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["8582"],"URL":"https:\/\/doi.org\/10.1007\/s12016-016-8582-3","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,11]]},"assertion":[{"value":"11 August 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}